Abstract

We have determined the pharmacological profile of the new serotonin 5-HT7 receptor agonist N- (4-cyanophenylmethyl)-4-(2-diphenyl)-1-piperazinehexanamide (LP-211). Radioligand binding assays were performed on a panel of 5-HT receptor subtypes. The compound was also evaluated in vivo by examining its effect on body temperature regulation in mice lacking the 5-HT7 receptor (5-HT7−/−) and their 5-HT7 +/+ sibling controls. Disposition studies were performed in mice of both genotypes. It was found that LP-211 was brain penetrant and underwent metabolic degradation to 1-(2-diphenyl)piperazine (RA- 7). In vitro binding assays revealed that RA-7 possessed higher 5-HT7 receptor affinity than LP-211 and a better selectivity profile over a panel of 5-HT receptor subtypes. In vivo it was demonstrated that LP- 211, and to a lesser degree RA-7, induced hypothermia in 5-HT7 +/+ but not in 5-HT7−/− mice. Our results suggest that LP-211 can be used as a 5-HT7 receptor agonist in vivo.

Autore Pugliese

• Lacivita Enza , Berardi Francesco , Leopoldo Marcello

Tutti gli autori

• LACIVITA E.;BERARDI F.;LEOPOLDO M.;PERRONE R.

Titolo volume/Rivista

Non Disponibile

Anno di pubblicazione

2010

ISSN

0304-3940

ISBN

Non Disponibile

Numero di citazioni Wos

49

Ultimo Aggiornamento Citazioni

Non Disponibile

Numero di citazioni Scopus

49

Ultimo Aggiornamento Citazioni

Non Disponibile

Settori ERC

Non Disponibile

Codici ASJC

Non Disponibile